




SPACS 2023

CANCER CAPITAL CORP
Rank 10 of 18





SPACS 2023

CANCER CAPITAL CORP
Rank 10 of 18

The relative strengths and weaknesses of CANCER CAPITAL CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CANCER CAPITAL CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 38% points. The greatest weakness of CANCER CAPITAL CORP is the variable Other Assets, reducing the Economic Capital Ratio by 212% points.

The company's Economic Capital Ratio, given in the ranking table, is -922%, being 308% points below the market average of -614%.

Input Variable	Value in 1000 USD
Assets, Current	22
Assets, Non-Current	0
General And Administrative Expense	21
Liabilities, Current	434
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-21
Other Revenues	0
Professional Fees	0

Output Variable	Value in 1000 USD
Assets	22
Liabilities	434
Expenses	21
Revenues	0
Stockholders Equity	-412
Net Income	-42
Comprehensive Net Income	-42
Economic Capital Ratio	-922%